Vivantes Netzwerk fuer Gesundheit GmbH

The department focuses on melanoma in patients with locally advanced or fully resectable disease, evaluating innovative neoadjuvant approaches to boost long‑term outcomes.

• Neoadjuvant intratumoral immunotherapy with cytokine‑based agents
• Integration of surgery and adjuvant therapy to enhance disease control
• Assessment of recurrence‑free survival as a primary endpoint

This work, conducted at Vivantes Netzwerk fuer Gesundheit GmbH, aims to reduce the risk of new metastases and provide patients with more durable remission.

Research targets metastatic non‑small cell lung cancer expressing high PD‑L1, testing combination immunotherapy to extend survival.

• Comparison of pembrolizumab alone with pembrolizumab plus sacituzumab govitecan
• Evaluation of progression‑free survival using RECIST criteria
• Overall survival outcomes in PD‑L1 ≥50% patients

The study seeks to identify more effective treatment regimens for advanced lung cancer, potentially improving patient longevity at the Berlin site.